FOXN2, identified as a novel biomarker in serum, modulates the transforming growth factor-beta signaling pathway through its interaction with partitioning defective 6 homolog alpha, contributing to the pathogenesis of gastric cancer

Liang Li,XueFeng Sun,Mei Zhang,BangShuo Zhang,Yi Yang,Sheng Wang
DOI: https://doi.org/10.1080/08977194.2023.2297700
2024-03-06
Growth Factors
Abstract:Background and Objective Dysregulated expression of Forkhead Box N2 (FOXN2) has been detected in various cancer types. However, the underlying mechanisms by which FOXN2 contributes to the onset and progression of gastric cancer (GC) remain largely unexplored. This study aimed to elucidate the potential role of FOXN2 within GC, its downstream molecular mechanisms, and its feasibility as a novel serum biomarker for GC.
cell biology,endocrinology & metabolism
What problem does this paper attempt to address?